Vertex Pharmaceuticals
NEWS
Although it was relatively quiet in COVID-19-related clinical trials, there was plenty of other clinical trial news. Here’s a look.
Exo Therapeutics’ approach is not only different, it has revolutionary potential.
Despite the massive financing from venture capitalists that poured into Massachusetts in 2021, Bay State biopharma companies are struggling to find enough talent to fill the number of available jobs.
The emerging generation of precision gene therapies addresses what has been one of this genre’s greatest challenges to date: the risk of unintended consequences.
Sangamo Therapeutics announced that Sanofi US was returning its rights to SAR445136 as it shifts its approach from personalized cell therapies to allogeneic off-the-shelf genomic approaches.
Companies large and small have increased the prices of their drugs so far this week. The drug price increases when the market is seeing high inflation.
Here’s a look at 10 of the more compelling research stories of the year.
Heading out of November and into December, plenty of companies had clinical trial news to report. Here’s a look.
The company plans to move it into Phase III studies in APOL1-mediated kidney disease, including FSGS, in the first quarter of 2022.
JOBS
IN THE PRESS